SecBot SecBot
DEFA14A ·Filed May 7, 2026

CPRX

CATALYST PHARMACEUTICALS, INC.
BULLISH
Impact 8/10
Horizonweeks Processed6mo ago SEC0001193125-26-212474
Proxy solicitation materials
Actionable Insight ▲ Bullish

The deal provides immediate and certain cash value at a premium. Traders should monitor the arbitrage spread, which will narrow as the close approaches. Key risks include regulatory hurdles and potential competing bids, though no go-shop provision suggests a clean path. Look for the definitive proxy statement for detailed terms and voting timeline.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$31.15
T+0 close · May 7, 2026 · via day close
Latest settled
+0.39%
T+20 · $31.27
Vs SPY
+0.36%
α at T+20
Next horizon
T+60
due 3mo ago
  1. T+0 · May 8 $31.15entry
  2. T+1 · 6mo ago 0.00%α −0.23% · $31.15
  3. T+5 · 6mo ago +0.03%α −1.43% · $31.16
  4. T+20 · 5mo ago +0.39%α +0.36% · $31.27
  5. T+60 · due 3mo ago Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Catalyst Pharmaceuticals (CPRX) filed additional proxy soliciting materials for its pending acquisition by Angelini Pharma for $31.50 per share in cash, representing a total equity value of approximately $4.1 billion. This all-cash deal offers a 21% premium to the unaffected closing price and a 28% premium to the 30-day VWAP, and has been unanimously approved by Catalyst's board. The transaction is expected to close in Q3 2026, subject to shareholder and regulatory approvals.

Key Financial Metrics

Vote
merger approval

Key Facts

  • Angelini Pharma acquires Catalyst for $31.50 per share in cash, total equity value ~$4.1 billion
  • 21% premium to unaffected closing price on April 22, 2026; 28% premium to 30-day VWAP
  • Catalyst Board unanimously approved; received fairness opinion from JP Morgan
  • No go-shop provision; termination fee is typical and customary
  • Expected close in Q3 2026, subject to shareholder vote and regulatory approvals

Financial Impact

$4.1 billion total equity value; $31.50 per share cash consideration representing 21-28% premium

share pricepremiumdeal value

Risk Factors

  • Shareholder approval may face dissident votes; though board is unanimous
  • Regulatory approvals, including antitrust clearance, could delay or block the transaction
  • Termination fee may deter competing bids but does not eliminate them entirely
  • Integration risk for Angelini Pharma as it establishes U.S. commercial presence

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-212474
Document: 0001193125-26-212474-index-headers.html0001193125-26-212474
Document: 0001193125-26-212474-index.html0001193125-26-212474
Document: 0001193125-26-212474.txt0001193125-26-212474

Track record

16 reports on CPRX

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +25.72% at T+60 after the Feb 25, 2026 report. 5 of 8 went positive at some point.

Filters
  1. Nov 4, 202612d ago Institutional Cluster Bearish 4/10 No price data
  2. Aug 22, 202612w ago Institutional Cluster Mixed 5/10 No price data
  3. Jul 24, 202616w ago 15-12G Bearish 9/10 Entry $31.49 No price data
  4. Jul 17, 202617w ago EFFECT Bearish 5/10 Entry $31.49 No price data
  5. Jul 15, 202617w ago 25-NSE Bearish 9/10 Entry $31.49 No price data
  6. Jul 8, 202618w ago 8-K Bullish 6/10 Entry $31.47 No price data
  7. Jun 30, 202619w ago DEFA14A Neutral 3/10 Entry $31.44 No price data
  8. Jun 30, 202619w ago 8-K Neutral 4/10 Entry $31.44 No price data
  9. May 28, 202624w ago PREM14A Bullish 8/10 Entry $31.23 to $31.46 ▲ +0.74% +2.53% vs SPY
  10. May 12, 202626w ago DEFA14A Neutral 3/10 Entry $31.14 to $31.34 ▲ +0.64% +2.37% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026